KVUE

#2793
Kenvue Inc. Common Stock
0.1 7 USD
-99.02%
Sektor: Konjunkturunabhängige Konsumgüter
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.17
0.18
Jahresspanne
0.17
19.18
Tagesänderung
-99.02%
Monatliche Änderung
-99.00%
6 month change
-99.00%
Jahresänderung
-98.85%
Vorheriger Schlusskurs
17.6 8
Open
0.1 8
Tief
0.1 7
High
0.1 8
Volumen
3 185
Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik Dividenden
Vierteljährlich Jährlich
Gewinn- und Verlustrechnung Bilanz Cashflow
Wert 202320242025 TTM

Kenvue Inc. Common Stock

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

Nachrichten